Company: ARWR
Filing Date: 2025-02-07
Form Type: DEFA14A
Source: 0001628280-25-004316
Chunk: 2

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-02-07
Form: DEFA14A
Chunk 2
---
 Mr. Ingram received his J.D. from the University of Arizona and his Bachelor of Science degree from Arizona State University.

Mr. Ingram will receive standard compensation and equity awards available to non-employee directors of the Company. The Company’s non-employee director compensation program is described in the “Director Compensation” section of the Company’s definitive Proxy Statement filed with the SEC on January 29, 2025. In addition, in connection with his appointment, Mr. Ingram shall receive a sign-on grant of restricted stock units valued at $771,200. These restricted stock units are scheduled to vest over three years.

There are no family relationships between Mr. Ingram and any of the Company’s directors or executive officers and, except as described below, Mr. Ingram does not have any direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.

As noted above, Mr. Ingram currently serves as the President and Chief Executive Officer of Sarepta, and is also a member of its board of directors. As previously reported in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 (the “2024 Form 10-K”), the Company entered into an Exclusive License and Collaboration Agreement (the “Collaboration Agreement”) with Sarepta for the co-development and commercialization of multiple clinical and preclinical programs on November 25, 2024. In connection with the Collaboration Agreement, the Company also entered into a Stock Purchase Agreement (the “Stock Purchase Agreement” and, together with the Collaboration Agreement, the “Agreements”) with an affiliate of Sarepta for a private placement of shares of common stock of the Company. For additional information on the Agreements, see “Item 9B. Other Information,” under the heading “(a) License and Collaboration Agreement,” of Part II of the 2024 Form 10-K. As a result of the closing of the Agreements on February 7, 2025, Mr. Ingram is not considered an independent director under the Nasdaq Listing Rules.

#### Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

| Exhibit No. |     | Description                                                                 |
| 104         |     | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on